Crystal Research Associates has issued a 12-page Quarterly Update on Hybrid Software Group PLC (HYSG-EBR), a developer of software and hardware enterprise solutions for industrial inkjet printing.
Posted by Karen Goldfarb
September 12, 2023 at 1:09 PM
Crystal Research Associates has issued a 12-page Quarterly Update on Hybrid Software Group PLC (HYSG-EBR), a developer of software and hardware enterprise solutions for industrial inkjet printing.
Topics: hybrid software group, hysg, inkjet printing, enterprise software, hardware, global graphics, color logic, ic3d, original equipment manufacturers, hybrid software
Posted by Karen Goldfarb
September 8, 2023 at 9:45 AM
Crystal Research Associates has issued a 9-page Quarterly Update on clinical-stage biotechnology company, Emmaus Life Sciences, Inc. (EMMA-OTCQX).
Topics: orphan diseases, EMMA, orphan drug, sickle cell crisis, The Steve Harvey Show, sickle cell disease, L-glutamine, endari, diverticulosis
Posted by Karen Goldfarb
August 11, 2023 at 2:33 PM
Crystal Research Associates has issued a 20-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, cancer, covid19, coronovirus, covid-19, monkeypox
Posted by Karen Goldfarb
May 11, 2023 at 11:54 AM
An Executive Informational Overview (EIO) is now available on Hybrid Software Group PLC, a developer of software and hardware enterprise solutions for industrial inkjet printing. The 80-page report details the Company's business, its strategy, market opportunities, competition, financials, risks, and more. It is available for download below.
Topics: hybrid software group, hysg, inkjet printing, enterprise software, hardware, global graphics, color logic, ic3d, original equipment manufacturers, hybrid software
Crystal Research Associates has issued an 18-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, cancer, covid19, coronovirus, covid-19, monkeypox
Posted by Karen Goldfarb
March 28, 2023 at 4:41 PM
Crystal Research Associates has issued a 16-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, cancer, covid19, coronovirus, covid-19, monkeypox
Posted by Karen Goldfarb
March 20, 2023 at 7:13 PM
An updated Executive Informational Overview (EIO) is now available on CEL-SCI Corporation, a clinical-stage biotechnology company developing immunotherapy technologies to treat cancer, autoimmune, and infectious diseases. The 98-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.
Topics: biotech, immunotherapy, CEL-SCI, infectious diseases, leaps, cancer, autoimmune, head and neck cancer, squamous cell carcinoma, rheumatoid arthritis, covid19, cervical dysplasia
Posted by Karen Goldfarb
January 24, 2023 at 3:17 PM
An Executive Informational Overview (EIO) is now available on Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies, primarily for rare and orphan diseases, with an initial focus on Sickle Cell Disease (SCD). The 76-page report details the Company's business, its strategy, market opportunities, competition, financials, risks, and more. It is available for download below.
Topics: orphan diseases, EMMA, orphan drug, sickle cell crisis, The Steve Harvey Show, emmaus life sciences, sickle cell disease, L-glutamine, endari, diverticulosis
Posted by Karen Goldfarb
December 21, 2022 at 2:30 PM
A 13-page Quarterly Update is now available on Bioxytran, Inc., a clinical stage pharmaceutical company developing therapeutics in two areas: (1) glycovirology and anti-viral therapeutics; and (2) hypoxic conditions, necrosis, and degenerative diseases.
Topics: covid19, coronovirus, SARS-CoV-2, galectrin-3, glycovirology, bioxytran, complex carbohydrate chemistry, galectin
Posted by Karen Goldfarb
November 11, 2022 at 4:11 PM
Crystal Research Associates has issued a 17-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, cancer, covid19, coronovirus, covid-19, monkeypox
Posted by Karen Goldfarb
September 14, 2022 at 8:29 PM
An Executive Informational Overview (EIO) is now available on SG Blocks, Inc., a leading developer, designer, and fabricator of modular structures, meeting the growing demand for safe and green construction. The 64-page report details the Company's business, its strategy, market opportunities, competition, financials, risks, and more. It is available for download below.
Topics: SG Blocks, modular construction, green building, COVID-19 testing, Starbucks, Taco Bell, Sanitec, green construction, shipping containers, GreenSteel, cargo modified modules, Verizon, Puma, Lacoste, NBA, Equinox, Clarity Lab Solutions, SGBX
An Executive Informational Overview (EIO) is now available on Bioxytran, Inc., a clinical stage pharmaceutical company developing therapeutics in two areas: (1) glycovirology and anti-viral therapeutics; and (2) hypoxic conditions, necrosis, and degenerative diseases. The 70-page report details the Company's business, its strategy, market opportunities, competition, financials, risks, and more. It is available for download below.
Topics: covid19, coronovirus, SARS-CoV-2, galectrin-3, glycovirology, bioxytran, complex carbohydrate chemistry, galectin
Posted by Karen Goldfarb
August 5, 2022 at 4:02 PM
Crystal Research Associates has issued a 19-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, cancer, covid19, coronovirus, covid-19, monkeypox
An Executive Informational Overview (EIO) is now available on Genprex, Inc., a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The 62-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.
Topics: cancer, REQORSA, genprex, diabetes, gene therapy, non-small cell lung cancer, small-cell lung cancer
Posted by Karen Goldfarb
May 18, 2022 at 11:06 AM
An Executive Informational Overview (EIO) is now available on ImmunoPrecise Antibodies Ltd, a full-service contract research organization (CRO) for therapeutic antibody discovery and development. The 72-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.
Topics: biotech, biopharmaceuticals, biotechnology, Oncology, Biologics, Humanized monoclonal antibodies, Immunoassay, Immunogen, Monoclonal antibody, Antibody, Contract research organization (CRO), Customer relationship management (CRM), Human monoclonal antibodies, SARS-CoV-2, Polyclonal antibody, Contract manufacturing organization (CMO), Enterprise resource planning (ERP)
We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.
CONTACT INFORMATION
Phone: (212) 851-6685